Ramipril Tablet
Description
MIPROOT-5
Ramipril 5 mg Tablets
Division: DIABGLYM
Composition
Each tablet contains:
Ramipril IP — 5 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Oral tablet
Product Description
MIPROOT-5 contains Ramipril 5 mg, a long-acting angiotensin-converting enzyme (ACE) inhibitor formulated for the effective management of hypertension, heart failure, post-myocardial infarction care, diabetic nephropathy, and long-term cardiovascular and renal protection. Ramipril provides sustained blood pressure control by inhibiting the renin-angiotensin-aldosterone system (RAAS), promoting vasodilation, reducing cardiac workload, and protecting vital organs from hypertension-related damage.
Ramipril is widely prescribed in cardiology, nephrology, and internal medicine for patients with essential hypertension, diabetes-associated hypertension, chronic kidney disease, heart failure, left ventricular dysfunction, and established cardiovascular disease. It helps reduce systolic and diastolic blood pressure, improve endothelial function, decrease arterial stiffness, reduce proteinuria, and lower the risk of myocardial infarction, stroke, heart failure progression, and cardiovascular mortality.
MIPROOT-5 is particularly beneficial for patients requiring effective blood pressure control, cardiovascular protection, renal preservation, and long-term ACE inhibitor therapy.
Technical Knowledge of Ramipril
Ramipril is converted in the liver to its active metabolite Ramiprilat, which inhibits angiotensin-converting enzyme. This reduces the formation of angiotensin II, decreases aldosterone secretion, promotes vasodilation, reduces sodium and water retention, improves endothelial function, and enhances arterial compliance.
Ramipril also reduces bradykinin degradation, contributing to improved vascular function and nitric oxide-mediated vasodilation. Its long duration of action provides effective once-daily blood pressure control and sustained cardiovascular and renal protection.
Mechanism of Action
Ramipril inhibits angiotensin-converting enzyme, reduces angiotensin II formation, decreases aldosterone secretion, promotes vasodilation, improves endothelial function, reduces peripheral vascular resistance, decreases cardiac afterload, and provides cardiovascular and renal protection.
Key Benefits
Effective reduction of systolic and diastolic blood pressure
Provides sustained 24-hour blood pressure control
Supports cardiovascular and renal protection
Improves endothelial function
Reduces arterial stiffness
Decreases cardiac workload
Helps reduce proteinuria
Suitable for long-term hypertension and cardiovascular management under medical supervision
Clinical Applications
MIPROOT-5 is commonly prescribed for essential hypertension, hypertension with diabetes mellitus, hypertension with chronic kidney disease, diabetic nephropathy, chronic heart failure, post-myocardial infarction management, left ventricular dysfunction, and long-term cardiovascular risk reduction.
Facts About Ramipril
Ramipril is an evidence-based ACE inhibitor with extensive clinical research demonstrating significant reductions in cardiovascular morbidity and mortality. It is widely recommended in international hypertension, heart failure, diabetic nephropathy, and coronary artery disease guidelines because of its proven benefits in blood pressure control, vascular protection, renal preservation, and prevention of major cardiovascular events.
Key Facts
Long-acting ACE inhibitor
Ramipril 5 mg for cardiovascular and renal protection
Provides sustained 24-hour antihypertensive action
Effective in hypertension, heart failure, and diabetic nephropathy
Supports long-term cardiovascular risk reduction
Evidence-based ACE inhibitor therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
MIPROOT-5 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, Nephrology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of hypertension, diabetes, chronic kidney disease, heart failure, and cardiovascular disorders creates strong prescription demand and long-term market potential for this formulation.
Why Choose MIPROOT-5 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Ramipril 5 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
MIPROOT-5 from DIABGLYM combines effective blood pressure control, comprehensive cardiovascular and renal protection, evidence-based ACE inhibitor therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, nephrologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Ramipril formulation.
